Artwork

Content provided by 95bFM: The Wire. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by 95bFM: The Wire or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

How Does The Weight-Loss Drug, Wegovy, Impact Obesity in Aotearoa W/ Boyd Swinburn: July 02, 2025

 
Share
 

Manage episode 492019049 series 1415376
Content provided by 95bFM: The Wire. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by 95bFM: The Wire or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Wegovy, also known as Ozempic when marketed in lower doses, is a weight-loss drug that is already making headlines globally, and now as of the 1st of July, it’s available for prescription in Aotearoa.

Given that New Zealand is currently ranked 31st in the world for obesity rates, according to The World Obesity Federation, some experts believe Wegovy could have a major impact on obesity levels nationwide. Especially if it were to become publicly funded.

To talk about why the drug isn’t publicly funded at the moment, and what kind of impact Wegovy could have on obesity in Aotearoa, Producer Max spoke with Boyd Swinburn, Professor of Population, Nutrition and Global Health at the University of Auckland.

  continue reading

1170 episodes

Artwork
iconShare
 
Manage episode 492019049 series 1415376
Content provided by 95bFM: The Wire. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by 95bFM: The Wire or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.

Wegovy, also known as Ozempic when marketed in lower doses, is a weight-loss drug that is already making headlines globally, and now as of the 1st of July, it’s available for prescription in Aotearoa.

Given that New Zealand is currently ranked 31st in the world for obesity rates, according to The World Obesity Federation, some experts believe Wegovy could have a major impact on obesity levels nationwide. Especially if it were to become publicly funded.

To talk about why the drug isn’t publicly funded at the moment, and what kind of impact Wegovy could have on obesity in Aotearoa, Producer Max spoke with Boyd Swinburn, Professor of Population, Nutrition and Global Health at the University of Auckland.

  continue reading

1170 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play